Century Therapeutics IPSC Stock
Century Therapeutics Price Chart
Century Therapeutics IPSC Financial and Trading Overview
| Century Therapeutics stock price | 0.5 USD |
| Previous Close | 3.29 USD |
| Open | 3.28 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1200 |
| Day's Range | 3.22 - 3.29 USD |
| 52 Week Range | 2.81 - 14 USD |
| Volume | 40.92K USD |
| Avg. Volume | 97.58K USD |
| Market Cap | 193.64M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.61 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.3 USD |
IPSC Valuation Measures
| Enterprise Value | -3404112 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.533019 |
| PEG Ratio (5 yr expected) | 0.1 |
| Price/Sales (ttm) | 33.038322 |
| Price/Book (mrq) | 0.69311154 |
| Enterprise Value/Revenue | -0.581 |
| Enterprise Value/EBITDA | 0.029 |
Trading Information
Century Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -62.077% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 14 USD |
| 52 Week Low | 2.81 USD |
| 50-Day Moving Average | 3.2 USD |
| 200-Day Moving Average | 6.35 USD |
IPSC Share Statistics
| Avg. Volume (3 month) | 97.58K USD |
| Avg. Daily Volume (10-Days) | 76.1K USD |
| Shares Outstanding | 59.58M |
| Float | 21.53M |
| Short Ratio | 16.82 |
| % Held by Insiders | 36.04% |
| % Held by Institutions | 55.27% |
| Shares Short | 1.3M |
| Short % of Float | 7.39% |
| Short % of Shares Outstanding | 2.18% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2192.048% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -15.95% |
| Return on Equity (ttm) | -37.56% |
Income Statement
| Revenue (ttm) | 5.86M USD |
| Revenue Per Share (ttm) | 0.1 USD |
| Quarterly Revenue Growth (yoy) | 62.60% |
| Gross Profit (ttm) | N/A |
| EBITDA | -118288000 USD |
| Net Income Avi to Common (ttm) | -124683000 USD |
| Diluted EPS (ttm) | -2.15 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 251.47M USD |
| Total Cash Per Share (mrq) | 4.22 USD |
| Total Debt (mrq) | 52.04M USD |
| Total Debt/Equity (mrq) | 18.78 USD |
| Current Ratio (mrq) | 9.245 |
| Book Value Per Share (mrq) | 4.689 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -101920000 USD |
| Levered Free Cash Flow (ttm) | -95021504 USD |
Profile of Century Therapeutics
| Country | United States |
| State | PA |
| City | Philadelphia |
| Address | 3675 Market Street |
| ZIP | 19104 |
| Phone | 267 817 5790 |
| Website | https://www.centurytx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 163 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Q&A For Century Therapeutics Stock
What is a current IPSC stock price?
Century Therapeutics IPSC stock price today per share is 0.5 USD.
How to purchase Century Therapeutics stock?
You can buy IPSC shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Century Therapeutics?
The stock symbol or ticker of Century Therapeutics is IPSC.
Which industry does the Century Therapeutics company belong to?
The Century Therapeutics industry is Biotechnology.
How many shares does Century Therapeutics have in circulation?
The max supply of Century Therapeutics shares is 91.05M.
What is Century Therapeutics Price to Earnings Ratio (PE Ratio)?
Century Therapeutics PE Ratio is now.
What was Century Therapeutics earnings per share over the trailing 12 months (TTM)?
Century Therapeutics EPS is -1.61 USD over the trailing 12 months.
Which sector does the Century Therapeutics company belong to?
The Century Therapeutics sector is Healthcare.
Century Therapeutics IPSC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.51B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.51B USD — |
| NASDAQ Global Select Market Com NQGS | 8495.19 USD — |
-0.11
|
— — | 8378.66 USD — | 8543.96 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4184.77 USD — |
+1.29
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
| NYSE COMPOSITE (DJ) NYA | 18971.73 USD — |
+0.38
|
— — | 18822.43 USD — | 19030.68 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
- {{ link.label }} {{link}}